Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement
Jazyk angličtina Země Itálie Médium print-electronic
Typ dokumentu kazuistiky, dopisy
PubMed
30765472
PubMed Central
PMC6518888
DOI
10.3324/haematol.2018.213157
PII: haematol.2018.213157
Knihovny.cz E-zdroje
- MeSH
- bicyklické sloučeniny heterocyklické farmakokinetika terapeutické užití MeSH
- chronická lymfatická leukemie mozkomíšní mok komplikace farmakoterapie patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- lokální recidiva nádoru mozkomíšní mok farmakoterapie patologie MeSH
- nádory centrálního nervového systému mozkomíšní mok komplikace farmakoterapie patologie MeSH
- prognóza MeSH
- protinádorové látky farmakokinetika terapeutické užití MeSH
- sulfonamidy farmakokinetika terapeutické užití MeSH
- tkáňová distribuce MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- Publikační typ
- dopisy MeSH
- kazuistiky MeSH
- Názvy látek
- bicyklické sloučeniny heterocyklické MeSH
- protinádorové látky MeSH
- sulfonamidy MeSH
- venetoclax MeSH Prohlížeč
Department of Oncology Istituto di Ricerche Farmacologiche Mario Negri IRCCS Italy
Hematology Unit IRCCS Ca' Granda Ospedale Maggiore Policlinico of Milan Italy
Zobrazit více v PubMed
Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–322. PubMed PMC
Ratterman M, Kruczek K, Sulo S, Shanafelt TD, Kay NE, Nabhan C. Extramedullary chronic lymphocytic leukemia: systematic analysis of cases reported between 1975 and 2012. Leuk Res. 2014;38(3):299–303. PubMed
Strati P, Uhm JH, Kaufmann TJ, et al. Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia. Haematologica. 2016;101(4):458–465. PubMed PMC
Moazzam AA, Drappatz J, Kim RY, Kesari S. Chronic lymphocytic leukemia with central nervous system involvement: report of two cases with a comprehensive literature review. J Neurooncol. 2012; 106(1):185–200. PubMed
Wanquet A, Birsen R, Lemal R, Hunault M, Leblond V, Aurran-Schleinitz T. Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia. Blood. 2016;127(19):2356–2358. PubMed
Salem AH, Agarwal SK, Dunbar M, Enschede SL, Humerickhouse RA, Wong SL. Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin lymphoma. J Clin Pharmacol. 2017; 57(4):484–492. PubMed
Salem AH, Hu B, Freise KJ, Agarwal SK, Sidhu DS, Wong SL. Evaluation of the pharmacokinetic interaction between venetoclax, a selective BCL-2 inhibitor, and warfarin in healthy volunteers. Clin Drug Investig. 2017;37(3):303–309. PubMed
Emami Riedmaier A, Lindley DJ, Hall JA, et al. Mechanistic physiologically based pharmacokinetic modeling of the dissolution and food effect of a biopharmaceutics classification system IV compound-The venetoclax story. J Pharm Sci. 2018;107(1):495–502. PubMed
Anderson MA, Deng J, Seymour JF, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016;1 27(25):3215–3224. PubMed PMC
